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Abstract 
TGFBIp is a constituent of the extracellular matrix in many human tissues including the 
cornea, where it is one of the most abundant proteins expressed. TGFBIp interacts with 
Type I, II, IV, VI and XII collagens as well as several members of the integrin family, 
suggesting it plays an important role in maintaining structural integrity and possibly corneal 
transparency as well. Significantly, more than 60 point mutations within the TGFBI gene 
have been reported to result in aberrant TGFBIp folding and aggregation in the cornea, 
resulting in severe visual impairment and blindness. Several studies have focused on 
targeting TGFBIp in the cornea as a therapeutic approach to treat TGFBI-linked corneal 
dystrophies, but the effect of this approach on corneal homeostasis and matrix integrity 
remained unknown. In the current study, we evaluated the histological and proteomic 
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profiles of corneas from TGFBI-deficient mice as well as potential redundant functions of the 
paralogous protein POSTN. The absence of TGFBIp in mouse corneas did not grossly affect 
the collagen scaffold, and POSTN is unable to compensate for loss of TGFBIp. Proteomic 
comparison of wildtype and TGFBI-/- mice revealed 11 proteins were differentially regulated, 
including Type VI and XII collagens. However, as these alterations did not manifest at the 
macroscopic and behavioral levels, these data support partial or complete TGFBI 
knockdown as a potential therapy against TGFBI-linked corneal dystrophies. Lastly, in situ 
hybridization verified TGFBI mRNA in the epithelial cells but not in other cell types, 
supportive of a therapy directed specifically at this lineage. 
 
Introduction 
Visual impairment has a negative impact on quality of life and is estimated to affect 
approximately 285 million people worldwide [1]. While some visual disorders such as myopia 
can be treated noninvasively by corrective lenses, other diseases require surgical 
intervention. The latter category includes 5q31-linked transforming growth factor beta-
induced (TGFBI) corneal dystrophies, a heterogeneous group of genetic disorders in which 
mutations within the TGFBI gene result in a progressive accumulation and aggregation of 
the secreted extracellular TGFBI protein (TGFBIp, UniProt entry Q15582) in the cornea [2]. 
Treatment of TGFBI-linked corneal dystrophies relies on surgical removal of the affected 
area using laser photoablation or ultimately replacing the affected cornea with a donor 
cornea. However, donor shortage and the recurrence of protein accumulation indicate the 
need to develop new treatment strategies. 
Several studies have suggested that downregulating corneal TGFBIp expression may be 
a way to treat dystrophic patients, using either siRNA-based methods [3-5] or drugs 
targeting the molecular pathways involved in TGFBIp expression [6]. However, the practical 
aspects of drug delivery and the potential side effects of the partial or complete elimination 
of one of the most abundant proteins in the human cornea remain unclear [7]. In addition, 
TGFBIp is known to interact with a wide range of extracellular macromolecules, including the 
proteoglycans decorin and biglycan [8] and Type I, II, IV, VI and XII collagens [9-12], and is 
thought to link cells to the extracellular matrix (ECM) through a number of integrin binding 
sites [13-19]. Additionally, TGFBIp is considered a matricellular protein, meaning that 
TGFBIp is rapidly turned over and could play a regulatory role via sequestration and 
modulation of specific growth factors [20]. Thus, changing the expression level of TGFBIp in 
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the cornea may have unforeseen consequences on the structural integrity of the cornea and 
aggravate the disease condition. 
In this study, we investigated the role of TGFBIp in maintaining the structural integrity of 
corneal cells and the collagenous matrix using a TGFBI-deficient mouse model (TGFBI-/-). A 
histological and ultrastructural examination demonstrated that TGFBIp deficiency has little to 
no effect on the gross structure of the cornea, which remained transparent, suggesting the 
existence of functional redundancy. Comparing the corneal proteomes of wildtype (TGFBI+/+) 
and TGFBI-/- mice resulted in the identification of 11 differentially expressed proteins; 
including Type VI and XII collagens, annexin A2, fibromodulin and fibulin-5 which are all 
known for their roles in maintaining corneal structural integrity. Thus, even though 
expression changes were observed at the molecular level, the macroscopic, microscopic 
and ultrastructural appearance of the TGFBI-/- mouse cornea was unaffected, indicating that 
partial or complete TGFBI knockdown would be a feasible treatment option for TGFBI-linked 
corneal dystrophies. 
 
Results 
Corneal origin of TGFBIp expression 
Systemic TGFBI-null mice were generated as previously described [21], and these mice are 
fully viable, fertile and indistinguishable from wildtype littermates. The corneal transparency 
and mouse behavior remained unaffected throughout adulthood, suggesting that TGFBI-/- 
mice have normal vision. To verify that TGFBIp protein deposition is completely absent in 
adult TGFBI-/- mouse corneas, we examined TGFBI mRNA and TGFBIp protein expression 
using in situ hybridization and immunoblotting (Figs. 1, 2).  In situ hybridization 
demonstrated that TGFBI mRNA is specifically expressed within the corneal epithelium (Fig. 
1A) and not seen in the stromal embedded keratocytes nor in the endothelium. Moreover, in 
situ hybridization confirmed that TGFBI mRNA is absent in TGFBI-/- mouse eyes (negative 
data not shown). Immunoblotting verified that TGFBIp was undetectable in the corneal tissue 
of TGFBI-/- mice and that a single 68-kDa TGFBIp band was present in isolated wildtype 
adult corneas (Fig. 2C). In addition, no obvious changes in the total protein expression 
profile were observed between TGFBI+/+ and TGFBI-/- corneal tissues subjected to SDS-
PAGE followed by Coomassie brilliant blue staining (Fig. 2B), indicating that there were no 
major alterations in protein expression in TGFBI-/- mice. 
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POSTN is located at the corneal periphery 
Additionally, we sought to determine if periostin (POSTN), a closely related gene family 
member of TGFBI [22], was similarly expressed. Although POSTN is widely expressed in 
adult organs under normal and pathological conditions [23], wildtype mouse corneas do not 
express POSTN mRNA. Using both in situ hybridization and real-time PCR data, we found 
that POSTN mRNA is absent in adult corneas (Figs. 1A, B), and thus is not co-expressed 
with TGFBI. Likewise, immunohistochemistry revealed that POSTN protein is deposited at 
the corneal periphery, where ciliary body/scleral venous sinus are (Fig. 1C). As the same 
degree of POSTN deposition was observed for wildtype and TGFBI-deficient mouse 
corneas, this also suggests a non-compensatory role for POSTN. The apparent discrepancy 
between site of POSTN mRNA expression and protein deposition indicates that corneal 
surrounding tissues are responsible for active POSTN expression, which then translocates 
to the corneal periphery. This is supported by a previous study showing that human POSTN 
is expressed by limbal stem cells which differentiate into the corneal epithelium [24]. 
 
Gross structure of the TGFBI-/- cornea appears normal 
To assess major effects of TGFBI knockout in mouse corneas, tissue sections of TGFBI+/+ 
and TGFBI-/- corneas were histologically compared (Fig. 2). No significant structural changes 
were observed in the stroma, or the Descemet’s membrane. Likewise, the epithelial and 
endothelial cell layers appeared unaffected in the TGFBI-/- corneas. Therefore, we conclude 
from these data that the absence of TGFBIp does not affect the gross architecture of the 
corneal structure. 
 
Proteomic analysis of TGFBI+/+ and TGFBI-/- corneas 
The histological observations described above led us to hypothesize that either TGFBIp is 
not essential for maintaining the structure of the developed cornea or functional redundancy 
exists due to the expression of other proteins to compensate for the lack of TGFBIp. To test 
these alternatives, a comparative analysis of the TGFBI+/+ and TGFBI-/- mouse cornea 
proteomes was performed. The iTRAQ MS analysis resulted in the quantification of 877 
proteins across all datasets, of which 516 proteins were quantified in all three biological 
samples of both the TGFBI+/+ and TGFBI-/- groups (Figs. 3 and Table SI). Of the 516 proteins 
quantified in all samples, 11 were significantly mis-regulated using a significance threshold 
of 0.01 and a fold change of at least 0.5 on the log2 scale (Table 1, Fig. 3). 
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POSTN does not compensate for TGFBIp deficiency in the cornea 
Of note, even though POSTN was above the significance threshold of 0.01 (p = 0.3), the 
protein was upregulated in TGFBI-/- mice, with a log2 fold change of 1.9 in the iTRAQ MS 
analysis (Table S1). Although POSTN is a TGFBIp paralog that exhibits high sequence 
similarity, and the two are often co-expressed, we show that POSTN mRNA is absent within 
the wildtype cornea (Fig. 1A, B). Increased POSTN protein levels in TGFBI-/- mice would 
support the idea that one or more proteins could compensate for the functional loss of 
TGFBIp. To test this, we performed a targeted quantitative selected reaction monitoring 
(SRM) analysis of POSTN in the three biological TGFBI+/+ and TGFBI-/- replicates in each 
group (Fig. 4). However, the LC-SRM-MS analysis supported the iTRAQ data and 
immunohistochemical staining and revealed no significant upregulation of POSTN protein in 
the TGFBI-/- mice, thus disproving the hypothesis that POSTN is upregulated to compensate 
for the lack of TGFBIp in the TGFBI-/- corneas. 
 
TGFBIp absence does not affect corneal ultra-structure 
The macroscopic appearance and animal behavior of the TGFBI-/- mice seem normal, 
although the proteomic analysis indicates several changes in expression of ECM proteins 
known to be expressed and involved in corneal stroma collagenous matrix organization. 
Consequently, we analyzed potential ultrastructural differences between TGFBI+/+ and 
TGFBI-/- mouse corneas using transmission electron microscopy (TEM), to quantify 
subepithelial collagen fibril diameters and interfibrillar spacing (Fig. 5). Collagen fibril 
diameters were similar for both TGFBI+/+ and TGFBI-/- corneas (mean: 30±3 vs. 31±3nm). 
However, the mean values of the center-to-center interfibrillar spacing were 58±10nm and 
62±11nm in the TGFBI+/+ and TGFBI-/- corneas, respectively. This supports the proteomic 
data and indicates that the collagenous matrix organization is marginally affected in TGFBI-/- 
corneas, resulting in a less densely packed collagen fibril corneal arrangement. 
 
Humans express elevated corneal TGFBIp amounts compared to mouse 
Unpublished observations suggest differential expression of TGFBIp between species. Mice 
appear to express substantial lower corneal levels of TGFBIp compare to human. In order to 
determine the degree of expression levels we performed a relative label-free MS1 
quantification between corneal TGFBIp in humans and mice. This analysis showed that 
human corneal TGFBIp levels exceed mice by more than 10-fold (Table S2). Thus, 
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completely removing TGFBIp as a therapy against corneal dystrophies in humans may result 
in a larger effect on the protein expression profile than observed in mice mutants. 
 
Discussion 
TGFBIp is a major constituent of adult cornea 
We have previously demonstrated that TGFBIp is one of the most abundant proteins in the 
human cornea [7]. We have also shown that TGFBIp and POSTN can exhibit both 
overlapping and mutually exclusive gene expression patterns [22], and that TGFBI null mice 
are viable and live a normal lifespan [21]. Our expression analysis (Fig. 1) revealed that only 
TGFBIp is robustly expressed in the adult corneal epithelium, suggesting continual secretion 
and deposition of TGFBIp from the epithelium into the corneal stroma. Additionally, we show 
that it is unlikely that the TGFBIp paralogue, POSTN, is able to compensate for the systemic 
loss of TGFBI (Fig. 1). However, future analysis of viable double TGFBI:POSTN knockout 
mice [25], will be helpful in determining whether low level corneal POSTN, as observed in 
both wildtype and TGFBI-/- corneas via iTRAQ MS analysis (Fig. 3), is sufficient to maintain 
normal corneal morphology and definitively conclude whether TGFBIp and POSTN indeed 
share any redundant and/or parallel functions in the adult cornea. 
 
Preservation of corneal integrity in TGFBI-/- mice 
Studies using mouse models lacking proteins important for proper corneal collagen 
architecture have demonstrated changes to the cornea including stromal thickness, 
disorganization of collagen fibrils and loss of transparency [26-29]. TEM of corneas from 
keratocan-null mice showed less organized collagen fibers than those of wildtype mice [27]. 
Corneas of lumican-null mice exhibited major changes in expression of ECM proteins when 
analyzed by a similar quantitative MS approach as performed in this study [28]. Severe 
disruption in collagen fibril structure and organization was observed in the corneas of a 
decorin and biglycan double-deficient mouse model [29], whereas fibromodulin was shown 
to be involved in and affect collagen fibrillogenesis in the peripheral cornea in fibromodulin-
deficient mice [26]. As TGFBIp binds several ECM proteins involved in collagen organization, 
it was anticipated that knocking out TGFBI would introduce changes in the collagenous 
matrix similar to that observed for keratocan-, lumican-, decorin/biglycan-, or fibromodulin-
deficient mice. However, our examination of TGFBI+/+ and TGFBI-/- mice did not reveal 
structural changes in the corneas of TGFBI-null mice. This is in agreement with observations 
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of the corneas from another TGFBI-deficient mouse model, where no histological changes or 
differences in animal development or behavior were observed [30]. 
 
  In addition to histological examination, our analysis of the ultrastructure using TEM only 
showed minor changes in collagen fibril diameter and interfibrillar spacing. This is in sharp 
contrast to the profound changes in the arrangement of collagen fibrils observed in the 
keratocan-, lumican-, decorin/biglycan- and fibromodulin-null mouse corneas [26-29]. 
However, the small changes in interfibrillar spacing seen in our TEM data support the 
findings in our quantitative proteomic analysis, which identified 11 proteins as being 
differentially expressed in the TGFBI-deficient mice (Table 1). Six of these proteins are 
known to be involved in the assembly of the collagen scaffold and cell adhesion to the ECM. 
The exact functional consequences of this expression profile alteration remain unclear, but it 
is likely that TGFBIp functions as a regulatory mediator between the ECM and the 
embedded corneal cell lineages. Whether TGFBIp directly interacts with these mis-
expressed ECM components and if they could themselves contribute to altered TGFBIp 
protein aggregation will be key in the development of therapeutic agents capable of 
dissolving and/or inhibiting the formation of mutant TGFBIp aggregates in the cornea. The 
recently published high resolution crystal structure of TGFBIp [31] (PDB entry: 5NV6) will 
provide new insight into the functional role of TGFBIp and its interaction to the extracellular 
matrix and may be a help to interpret and link to the differential expressed proteins identified 
in this study. 
 
   The TGFBIp paralog POSTN is well characterized as a matricellular protein [32], a term 
that may also be applied to TGFBIp. Matricellular proteins are a diverse group of non-
structural molecules present in the ECM that are vital for maintaining the integrity of the 
ECM in health and disease. In addition to being important components of the ECM itself, 
matricellular proteins also play crucial regulatory roles and can modulate cellular responses 
to extracellular signals induced during tissue remodeling and repair as well as in numerous 
disease states [33]. Interestingly, matricellular protein-deficient mice models often show mild 
changes in phenotypic appearance [33], which correlates well with the observations of the 
mouse model presented in the current study. 
 
Differential expression of collagen scaffold proteins 
The cornea accounts for approximately 70% of the refractive power of the eye and together 
with the aqueous humor and the lens protects the retina from UV light [34, 35]. Corneal 
transparency is dependent on the highly ordered collagen network found in the stroma 
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comprising approximately 90% of the corneal thickness. The corneal collagen network 
consists of approximately 200 interwoven lamellae, and each lamella consists of collagen 
Types I and V heterotypic fibrils arranged in a hexagonal pattern [36]. Collagen Types VI, XII 
and XIV together with the proteoglycans decorin, lumican, keratocan, mimecan, biglycan 
and fibromodulin provide structural support for proper collagen fibril assembly and spacing 
[37]. Notably, Types VI and XII collagens were upregulated in our LC-MS/MS analysis, and 
both collagen types have previously been shown to covalently bind TGFBIp [9, 12]. This 
suggests that one of the important physiological roles of TGFBIp is to bind Type VI and XII 
collagen and thereby participate in matrix organization and regulation of collagen constituent 
composition. TGFBIp was found to be upregulated in the cartilage of a collagen Type IX-
deficient mouse model [38]. Both Type IX and XII collagens belong to the FACIT (Fibril 
Associated Collagens with Interrupted Triple helices) collagen family and may therefore 
share similar functionalities. In addition to increased levels of TGFBIp in the cartilage of the 
Type IX collagen-deficient mouse, a change in TGFBIp degradation was observed. This is 
noteworthy because corneal TGFBIp is similarly proteolytically processed [39-41], implying 
that TGFBIp degradation is sensitive to changes in its matrix environment. 
   In addition to increased expression of Type VI collagen, we observed annexin A2 
upregulation. Annexin A2 has been suggested to mediate secretion of Type VI collagen in 
epithelial cells [42], and we found that these two proteins were upregulated to a comparable 
extent, supporting a similar connection in our mouse mutant model. 
   Furthermore, our iTRAQ analysis indicated highest upregulation of fibromodulin, one of the 
proteoglycans involved in accurate matrix assembly. Fibromodulin is expressed in the 
developing cornea but is located only peripherally in the mature cornea [26]. Even though no 
interaction between fibromodulin and TGFBIp has been reported in the literature, the 
fibromodulin homologs decorin and biglycan have both been shown to bind TGFBIp in a 
non-covalent manner [8]. Hence, fibromodulin may possess unappreciated binding 
properties similar to those of decorin and biglycan. In our previous quantitative analysis of 
corneal proteins, decorin and biglycan are among the most abundant proteins in the corneal 
stroma and endothelium [7]. Moreover, TGFBIp has been shown in vitro to enhance the 
effect of biglycan and decorin on Type VI collagen aggregation, and decorin/biglycan 
double-deficient mice display major defects in collagen fibril morphology [29]. However, 
decorin and biglycan interactions with TGFBIp may be less pronounced in the mouse 
cornea, as neither protein was represented on our list of differentially regulated proteins 
(Table 1), and no major alterations in collagen fibril diameter or spacing was observed in the 
TGFBI-deficient mouse corneas, as indicated by our TEM analysis. 
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   Prolargin, like lumican, decorin and biglycan, is a small leucine-rich repeat proteoglycan. 
Prolargin has been shown to be a major proteoglycan of both the sclera and the cornea [7, 
43] and can bind Type I collagen and function as an anchor between the ECM and 
basement membranes. Thus, the fact that TGFBI knockout results in an upregulation of 
prolargin in the mouse cornea suggests that TGFBIp may play a role in anchoring the 
stromal collagen scaffold to the epithelium basement membrane. 
   Fibulin-5 has been shown to be important for elastic fiber organization but does not affect 
collagen assembly [44], and we have previously identified it as one of the more abundant 
proteins in the Descemet’s membrane [45] and endothelial layer in the cornea [7]. It contains 
the RGD integrin-binding motif that is also found in TGFBIp [46]. This motif mediates binding 
to cells; hence, the significant fibulin-5 upregulation we observed may act to compensate for 
loss of TGFBIp cell adhesion. Whether fibulin-5 is able to form a complex with TGFBIp via 
the RGD motif and why fibulin-5 is upregulated in the absence of TGFBIp may be important 
for our understanding of normal cell adhesion in the cornea. 
 
TGFBI knockdown as a therapeutic treatment in corneal dystrophies 
The genetic origins of TGFBI-associated corneal dystrophies are heterogeneous, with new 
disease-causing mutations being reported on a regular basis. Therefore, a therapeutic 
strategy with a broad effect is desirable. This strategy could rely on suppression of the 
disease-causing protein. Several groups have addressed this using ex vivo and in vitro 
systems. Courtney et al. used siRNA targeting only the mutant allele of TGFBI in 
heterozygous primary corneal epithelial cells from a patient with lattice corneal dystrophy [3]. 
As this allele-specific strategy only knocked down the mutant protein, the patient still 
expressed wildtype TGFBIp in the cornea and therefore presumably exhibited a non-affected 
cornea. The same group later demonstrated the use of mutant allele-specific suppression of 
keratin 12 using CRISPR/Cas9 in a model of Meesmann’s epithelial corneal dystrophy. They 
concluded that a similar approach may be applicable to a substantial number of the TGFBI 
mutations reported to date [47]. However, the allele-specific approach can only be applied to 
heterozygous patients, whereas for homozygous patients, complete TGFBI knockdown will 
be required. Combined, our data indicate that it is possible to maintain structural integrity 
and to sustain protein expression following a complete removal of TGFBIp in the mouse 
cornea. This opens up possibilities for therapeutic strategies relying on complete elimination 
of TGFBIp. Yuan et al. and Yellore et al. both address this possibility using siRNA for total 
TGFBI knockdown in human corneal cell lines [4, 5], whereas Choi et al. used lithium 
treatment on corneal fibroblasts to inhibit TGFBIp expression [6]. In the latter case, lithium 
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treatment affected the upstream signaling pathway involved in TGFBIp expression, which 
likely affects the expression of many other proteins including TGFBIp, giving rise to 
undesirable side-effects. Another consideration in the design of therapies, is which corneal 
cell to target for TGFBIp suppression or knockdown to achieve the desired effect. Our in situ 
hybridization data (Fig. 1) show that TGFBI mRNA is restricted to the corneal epithelium and 
does not appear to be transcribed by the corneal keratocytes embedded in the stroma or in 
the innermost endothelial layer of the cornea. This suggests that generation of a therapy 
against TGFBI-related corneal dystrophies can be achieved by targeting only the corneal 
epithelium, which in terms of therapeutic delivery would most likely be less complicated than 
targeting all corneal cell types. Of note, Allaman-Pillet et al. showed that corneal TGFBIp 
was mainly present in the corneal stroma [30], suggesting that TGFBIp is expressed and 
secreted by the epithelium and diffuses throughout the underlying cornea. This may also 
partly explain why the epicenter of TGFBIp deposition in the corneal stroma appears to be 
different depending on the site and type of mutation in the TGFBI gene [48]. Recently, Liu et 
al. using quantitative PCR showed TGFBI mRNA expression in human keratocytes [49], 
however the authors did not compare mRNA expression levels between corneal cell types 
and the contribution by keratocytes may be significant lower than seen for the epithelium as 
supported from our in situ hybridization data. Our unpublished observation of human 
corneas maintained in culture medium where the epithelial layer has detached, shows 
unusual low levels of TGFBIp in the stroma when analyzed by mass spectrometry than 
normally seen for corneas without pre-detachment of the epithelium. Hence, all together we 
interpret these data as that the majority of TGFBIp originate from the corneal epithelium. 
This assumption is also supported by in situ hybridization experiments on rabbit corneas 
only detecting TGFBI mRNA in the epithelium [50]. Lastly, it should be noted with care that 
corneal TGFBIp expression levels in humans and mice differ substantially. The relative 
comparison between TGFBIp expression levels shows that it is 10-fold more abundant in 
humans than in mice (Table S2), which may amplify the minor changes observed in ECM 
arrangement in our TGFBI-null mouse to a more severe situation in humans. 
Several potential non-invasive therapeutic strategies to treat TGFBI-linked corneal dystrophy 
have been published, all relying on partial or complete knockdown of TGFBIp without 
considering the consequences of this on corneal homeostasis and integrity. In this study, we 
examined TGFBIp expression and characterized the gross structural and proteomic changes 
in mice deficient in TGFBIp compared to wildtype mice. Our data revealed only minor 
changes in the structure of the corneas in the TGFBI-null mice. In addition, the expression 
levels of only a few proteins were affected upon removal of TGFBIp. Hence, these data 
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suggest that total TGFBIp knockdown in corneas is a viable therapeutic strategy for the 
treatment of TGFBI-linked dystrophic patients. 
 
Experimental Procedures 
Transgenic mice  
Mice with null genetic deletions of POSTN or TGFBI were generated and genotyped as 
previously described [21, 51]. After euthanization, eyes from TGFBI+/+ and TGFBI-/- adult 
mice (8-10 weeks) and POSTN-/- adult (8-10 weeks) were harvested in cold phosphate-
buffered saline (PBS) and either placed immediately in liquid nitrogen or fixed in 4% 
paraformaldehyde or 4% paraformaldehyde/2% glutaraldehyde. Equal ratios of male and 
female mice were used in all experiments, and the mice are maintained on a C57BL/6J 
background. The mice were housed in standard barrier rack cages supplied with Purina 
Rodent Chow 5001 with automatic watering dispensers. All procedures were performed with 
the approval of the Institutional Animal Care and Use Committee at Indiana University 
School of Medicine (Indianapolis, IN; protocol 10807). 
 
RNA Isolation and Quantitative PCR 
mRNA from micro-dissected 10 week old adult wildtype corneas (n = 6 corneas from 3 mice) 
was isolated using RNAEasy (Qiagen, Venlo, The Netherlands) kit.  To compare TGFBI and 
POSTN mRNA expression levels within isolated cornea, we used quantitative PCR (qPCR) 
on cDNA synthesized using a Superscript-II kit (Invitrogen, Waltham, MA). cDNA was 
amplified within the linear range using primers (TGFBI forward 5’-
ACCATGGACCGGATGTTGAC-3’ and reverse 5’- GGCCACCAGCATGCTAAAAC-3’;  
POSTN forward 5’-AAGGAAAAGGGTCATACACGTACTTC-3’ and reverse 5’-
CCTCTGCGAATGTCAGAATCC-3’ from Qiagen) and normalized to GAPDH (PPM02946E-
200), as described [52]. qPCR reactions were carried out using SyberGreenER (Invitrogen) 
and run on the same plate. All qPCR results are representative of three separate 
experiments (n = 3) and ΔΔCt based fold-changes were calculated using GAPDH as a 
housekeeping standard. 
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In situ hybridization and Immunohistochemistry 
Murine 8-10 week old eyes were harvested, fixed in 4% paraformaldehyde overnight at 4°C, 
dehydrated through a graded ethanol series, cleared in xylenes, and processed for paraffin 
embedding and sectioning at 10μm thickness. Sense and anti-sense [35S]UTP-radiolabeled 
TGFBI and POSTN cDNA probes were transcribed for in situ hybridization, as previously 
described [22]. Following de-waxing and in situ analysis, a specific signal pattern was 
observed only with the anti-sense probe and was detected in at least three consecutive 
wildtype eye sections (n = 3). Subsequently, following de-waxing, whole wildtype, TGFBI-/- 
and POSTN-/- eye sections were used to examine POSTN protein deposition. POSTN was 
detected using a rabbit polyclonal antibody (1:10,000 dilution) and ABC kit (Vectorstain, 
Burlingame, CA) with DAB and hydrogen peroxide as a chromogen, as described [53]. Serial 
sections probed with the POSTN antibody were examined for signal detection in consecutive 
sections in at least three eyes of each genotype (n = 3 per genotype). 
 
SDS PAGE  
Equal amounts of TGFBI+/+ and TGFBI-/- corneal tissue were boiled for 10-min in SDS 
sample buffer under reducing condition (5mM dithiotreitol), and separated on 5-15% (w/v) 
gradient polyacrylamide sodium dodecyl sulfate gels, cast in-house [54]. 
 
Western blotting 
The SDS-PAGE gels were equilibrated with blotting buffer consisting of 10mM CAPS, pH 11, 
10% methanol (VWR chemicals) and transferred to polyvinylidene difluoride (PVDF) 
membranes (Immobilon-P, Millipore, Billerica, MA) by electroblotting at 0.5A for 15min. The 
membranes were blocked using 5% milk (Milex 240) in TBS-T for an hour at 23°C followed 
by incubation overnight at 4°C with rabbit polyclonal anti-TGFBIp serum [12] diluted 
1:10,000 in 2% skim milk TBS-T. The following day, the membrane was washed three times 
in TBS-T before incubation with secondary antibodies against rabbit (peroxidase conjugated 
anti-rabbit IgG, Sigma Aldrich, Missouri, US) diluted 1:25,000 in 2% skim milk TBS-T for two 
hours at 23°C. Finally, the membrane was developed using Amersham Hyperfilm and the 
enhanced chemiluminescence (ECL) kit (GE healthcare Life Sciences, Chalfont, UK). 
 
Light microscopy 
Formaldehyde-fixed and paraffin-embedded TGFBI+/+ and TGFBI-/- corneal tissue sections 
7μm thick were cut perpendicular to the epithelium. The sections were deparaffinized and 
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stained with toluidine blue using standard histological procedures. Histological examinations 
(n = 6 eyes from each genotype) were performed using light microscopy. 
 
Preparation of corneas for mass spectrometry 
Eyes from TGFBI+/+ control mice and TGFBI-/- mice (n = 6 eyes from each genotype) were 
removed and immediately frozen in liquid nitrogen. The corneas were subsequently excised 
using a 2mm biopsy needle (Miltex, Tuttlingen, Germany) and washed three times in 200µL 
of ice cold PBS and once in 1mL of PBS. The corneas from two mice were pooled, resulting 
in three biological replicates within each group, and lyophilized in a Speed-Vac concentrator 
(Thermo Scientific, Waltham, MA) for 18h. Proteins were then chemically cleaved by adding 
100µL of 0.66M CNBr in 70% trifluoroacetic acid and incubating at 23°C for 20h. The digest 
was then lyophilized and washed twice in 500µL of Milli-Q H2O with intermittent drying in the 
Speed-Vac. The washed samples were then dissolved in 100µL of 8M urea, 0.2M Tris-HCl, 
pH 8.3, and the peptide concentrations were determined using a 2-D Quant Kit (GE 
Healthcare Life Sciences, Little Chalfont, United Kingdom). Disulfide bridges were reduced 
by incubating with 10mM dithiothreitol for 1h at 23°C. The reduced cysteines were then 
alkylated by adding 30mM iodoacetamide and incubating for 1h in the dark at 23°C. The 
samples were then diluted five times in 0.1M Tris-HCl, pH 8.3, and 10µg was incubated 
overnight at 37°C with 200ng of trypsin (Promega, Madison, WI). The samples were 
centrifuged for 5min at 17,000 x g to remove precipitates, and the supernatants were 
desalted using POROS R2 C8/C18 resin (Life Technologies, Paisley, UK) packed in 200µL 
gel-loading pipet tips. 
 
iTRAQ labeling and strong cation exchange (SCX) fractionation 
For each biological sample, 2.5µg of desalted peptide was pooled in a reference “master 
mix” to be labeled with iTRAQ 114, and 7.5µg of each sample was dissolved in 25µL of 
iTRAQ dissolution buffer (Life Technologies, Carlsbad, CA, US). The samples were labeled 
with 4plex iTRAQ (115, 116, or 117) reagents according to the manufacturer’s protocol, 
resulting in two iTRAQ sets to be analyzed by LC-MS/MS. Briefly, each iTRAQ label was 
diluted with 50µL of ethanol, mixed with the sample and incubated for 2h at 23°C. The 
samples were then mixed, lyophilized and desalted using POROS R2 C8/C18 resin as 
described above. The two iTRAQ sets were then applied to an SCX column (PolyLC Inc., 
Columbia, MD) equilibrated in 30% acetonitrile, 5mM KH2PO4, pH 2.7 and eluted with a 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
linear gradient from 0mM to 500mM KCl in 30% acetonitrile, 5mM KH2PO4, pH 2.7. Eluted 
peptides were collected in 12 fractions including the flow-through for each iTRAQ set. Each 
fraction was desalted using POROS R2 micro purification and lyophilized. 
 
LC-MS/MS of iTRAQ samples 
Samples were dissolved in 0.1% formic acid and analyzed by nanoflow LC-MS/MS on an 
EASY-nLC II system (Thermo Scientific, Waltham, MA, US) coupled to a TripleTOF 5600 
mass spectrometer (Sciex, Framingham, MA, US). The samples were loaded on a 
0.1x21mm C18 trap column and a 0.075x100mm C18 analytical column (NanoSeparations, 
Nieuwkoop, Netherlands). Peptides were eluted and electrosprayed directly into the mass 
spectrometer using a 50min gradient from 5-40% acetonitrile in 0.1% formic acid at a flow 
rate of 250nL/min. The data were acquired using an ion spray voltage of 2.3kV, a curtain gas 
setting of 30 and an interface heater temperature of 150°C.  
 
Processing of iTRAQ data 
All 12 wiff files generated for either iTRAQ set 1 or 2 were searched simultaneous against 
the SwissProt Mus musculus database (2016_8) using ProteinPilot v.4.5 (Sciex, 
Framingham, MA) and the Paragon algorithm v. 4.5.0.0. Trypsin was specified as the 
digestion enzyme, allowing up to 5 missed cleavages. Iodoacetamide was entered as a fixed 
modification of cysteine, and the default standard workup modification set was used as the 
variable modifications. The instrument setting was specified as TripleTOF 5600, defining the 
default charge state and mass accuracy of the instrument, and the iTRAQ 4plex (peptide 
labeled) protocol was selected as the sample type. Quantitative data were normalized using 
the bias and background corrections to correct for any experimental and technical bias. 
Thorough ID and false discovery rate (FDR) analysis were both selected. The searches 
were imported to and parsed using MS Data Miner v. 1.3.0 [55], using a 1% global FDR at 
the protein level. To find significantly mis-regulated proteins, Student’s t-test with a 
significance threshold of 0.01 was performed for proteins quantified in all 3 biological 
replicates of both the TGFBI+/+ and TGFBI-/- groups. Proteins with a p-value less than 0.01 
and a minimum fold change of 0.5 on the log2 scale were considered up- or downregulated 
in TGFBI-/- mice. TGFBIp was excluded from the data processing, as it is not possible to 
obtain a ratio between TGFBI+/+ and TGFBI-/- samples. 
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Targeted MS analysis of POSTN – LC-SRM-MS 
The SRM assay was developed using Skyline 1.4.0.4421 [56] and based on the optimization 
of 4 stable isotope-labeled POSTN analog peptides (SpikeTides, JPT Peptide Technologies 
GmbH, Germany) (DQGPNVCALQQILGTK (+2), NGVIHLIDEVLIPDSAK (+2), 
LLYPADIPVGNDQLLELLNK (+2), and IIDGVPVEITEK (+2)). The final optimized assay 
included 4 transitions per peptide monitored, including both light and heavy peptide variants. 
New digests of TGFBI+/+ and TGFBI-/- corneas were prepared as described above. The LC-
SRM-MS analysis was performed on an EASY-nLC II system (Thermo Scientific, Waltham, 
MA, US) connected in-line to a Qtrap 6500 mass spectrometer (Sciex) equipped with a 
NanoSpray III source (AB Sciex) and operated under Analyst 1.6.1 control. Peptides were 
eluted at a flow rate of 250nL/min using a 12min gradient from 5% to 35% phase B (0.1% 
formic acid and 90% acetonitrile), followed by re-equilibration for 10min to the starting 
conditions. The Qtrap 6500 was used in positive ion mode with an ion spray voltage of 25kV, 
a curtain gas setting of 30, an ion source gas setting of 5 and an interface heater 
temperature of 150°C. The eluted peptides were measured with a scheduled (3min window) 
SRM method using a 20ms dwell time for all transitions (32 in total) and a target scan time of 
0.8s. 
 
Relative comparison of human and mouse corneal TGFBIp amounts 
Human tissue was used with full ethical approval and in accordance with the Declaration of 
Helsinki. Equal amounts of post-mortem healthy human cornea (n = 2, female, age 86; and 
male, 79) and wildtype mouse cornea (n = 2, 8-10 weeks) were processed as described 
above using a combination of CNBr chemical cleavage and trypsin digestion. The digested 
samples were normalized according to the OD280 value, and equal amounts were subjected 
to LC-MS/MS analysis using a method allowing for post-acquisition label-free quantification 
at the MS1 level. Wiff files were imported to Skyline 1.4.0.4421 [56], and four TGFBIp 
peptides (NNVVSVNK, QHGPNVCAVQK, STVISYECCPGYEK, SPYQLVLQHSR) identical 
in sequence between species were used for a relative MS1 quantitative comparison (Table 
S2). 
 
Transmission electron microscopy (TEM) 
Corneas from TGFBI-/- and age-matched TGFBI+/+ controls (n = 2 corneas from each 
genotype), which had all been stored at -20 °C before use, were fixed in 4% 
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paraformaldehyde, 2% glutaraldehyde, and 0.1M sodium cacodylate, pH 7.2 and postfixed 
with 1% osmium tetroxide followed by 0.5% uranyl acetate. The corneas were then 
dehydrated using an ethanol series and propylene oxide. The corneal specimens were 
infiltrated and embedded using an EMbed 812 Kit according to the manufacturer’s protocol 
(Electron Microscopy Sciences, Hatfield, PA.). Thin sections of 40-60nm on average were 
cut using a Leica Ultracut UCT  (Leica Mikrosysteme, Vienna, Austria) with a 45° diamond 
knife (Diatome, Biel, Switzerland) and post-stained with saturated aqueous uranyl and lead 
citrate [57]. The samples were imaged on a Tecnai G2 Spirit transmission electron 
microscope (FEI, Hillsboro, Oregon) equipped with a TemCam F416 CCD camera (Tvips, 
Gauting, Germany), operating at 120kV. All micrographs used in the morphometric analysis 
represent the central anterior corneal stroma and were acquired at 11,000× magnification. 
 
Morphometric analysis of collagen fibrils 
TEM micrographs were analyzed using ImageJ v.1.42q software (imagej.nih.gov). Collagen 
fibril diameter (n = 250) and center-to-center interfibrillar spacing (n = 250) were measured 
for TGFBI-/- and TGFBI+/+ corneas (n = 2 corneas from each genotype). Each measurement 
relied on 5 randomly chosen TEM micrographs per cornea, all representing the central 
anterior stroma. 
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Supporting Information 
Table S1: Proteins quantified in all biological replicates of both TGFBIp wildtype and 
deficient mice corneas. 
Table S2: Relative comparison of human and mouse corneal TGFBIp. 
 
Table 1 
Table 1. Differential expressed proteins in TGFBI
-/-
 corneas 
Accession
Nr 
Name 
 
Mass kDa 
 
P - value 
 
Log2  
(
-/-
/
+/+
) 
P40124 Adenylyl cyclase-associated protein 1 51.565 0.003 -0.76 
P07356 Annexin A2 38.676 0.004 1.00 
Q60847 Collagen alpha-1(XII) chain 340.214 0.004 1.98 
Q02788 Collagen alpha-2(VI) chain 110.334 0.005 0.94 
P50608 Fibromodulin 43.055 0.003 2.38 
Q9WVH9 Fibulin-5 50.193 0.005 2.34 
P14602 Heat shock protein beta-1 23.014 0.002 -1.51 
Q9Z331 Keratin, type II cytoskeletal 6B 60.322 0.001 0.96 
Q9JK53 Prolargin 43.293 0.003 0.64 
Q9R1P1 Proteasome subunit beta type-3 22.965 0.003 -0.62 
P07724 Serum albumin 68.693 0.006 -2.09 
Table shows mis-regulated proteins in TGFBI
-/-
 compared to TGFBI
+/+
 mice corneas with a p 
value below 0.01 and a minimum 0.5 fold mis-regulation on the log2 scale. 
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Figure legends 
 
Figure 1. TGFBIp and POSTN expression in the cornea 
(A) In situ hybridization analysis of TGFBI and POSTN mRNA in wildtype mouse corneas. A 
strong signal (indicated via silver grains) for TGFBI mRNA is restricted to the corneal 
epithelium, whereas no apparent signal is observed for POSTN mRNA (scale bar = 20µm). 
(B) Real-Time PCR supports the presence of TGFBI and the lack of POSTN mRNA in 
isolated corneal tissues (n = 3). Error bars represents the SD. (C) Immunohistochemically 
staining using a POSTN antibody verifies the absence of POSTN in the central cornea and 
reveals that POSTN protein is localized at the corneal periphery. Moreover, the extent of 
POSTN deposition in wildtype and TGFBI-/- mice corneas is unchanged, whereas no POSTN 
was detected in POSTN-/-  corneas (scale bars = 100µm). 
 
 
 
Figure 2. TGFBI-/- corneas show no aberrant changes 
(A, B) No morphological changes are observed throughout the corneal in sections of (A) 
TGFBI+/+ and (B) TGFBI-/- corneas examined by light microscopy. Tissue sections are 
stained with toluidine blue; a 4x objective was used. (C) SDS-PAGE of TGFBI-/- corneas 
shows no major differences in protein expression when compared to control TGFBI+/+ 
corneas. (D) Western blotting using TGFBIp anti-serum confirms complete knockout in the 
TGFBI-deficient mouse eyes. 
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Figure 3. The ECM of TGFBI-deficient corneas is affected at the protein level 
The relative quantification of TGFBI+/+ and TGFBI-/- corneas using the iTRAQ methodology 
followed by LC-MS/MS resulted in 516 proteins being quantified in all three biological 
replicates of both the TGFBI+/+ and TGFBI-/- groups. The volcano plot shows the 
TGFBI+/+/TGFBI-/- ratio distribution of quantified proteins using the log2 scale compared to 
the log2 of the p-values. Using a p-value cut-off of 0.01, we identified 11 proteins (Table 1) 
that were differentially expressed in the TGFBI-/- cornea (empty dots). Six proteins (Type VI 
collagen, Type XII collagen, annexin, fibromodulin, prolargin and fibulin-5) known for their 
role in ECM arrangement were among the significantly mis-regulated proteins identified, 
suggesting that the ECM is altered in the TGFBI-/- cornea. The arrow indicates POSTN, a 
TGFBIp paralog, that shows a 1.9-fold upregulation on the log2 scale in the TGFBI-/- cornea; 
however, it was not significantly mis-regulated at p<0.01. 
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Figure 4. The TGFBIp paralog POSTN does not compensate for the lack of TGFBIp 
expression 
(A, B) Targeted LC-SRM-MS assay was developed to assess whether the TGFBIp paralog 
POSTN is upregulated in the TGFBI-/- cornea to compensate for loss of TGFBIp. POSTN 
was one of the most regulated proteins in the iTRAQ analysis; however, its change in 
expression was not significant at p<0.01. The SRM assay was designed to monitor four 
proteotypic peptides for POSTN, including four transitions per proteotypic peptide. Each 
represent one of the biological replicates (n = 3) and show the intensity of the four transitions 
for the tryptic POSTN peptide IIDGVPVEITEK in TGFBI+/+ (A) and TGFBI-/- (B). (C) No 
significant difference between the TGFBI+/+ and TGFBI-/- groups (n = 3) was observed using 
a Student’s t-test and a p-value cut-off of 0.01, thus rejecting the hypothesis that the 
functional loss of TGFBIp in the TGFBI-deficient cornea is compensated by POSTN 
upregulation. Error bars represents the SD. 
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Figure 5. Stromal interfibrillar spacing is slightly affected in TGFBI-/- corneas 
(A-D) TGFBIp is known to interact with Type VI and XII collagens, which were both mis-
regulated in the iTRAQ analysis (Table 1). To investigate the effect of TGFBI deficiency on 
the delicate collagen architecture of the cornea, TEM micrographs were taken of TGFBI+/+ 
(A, B) and TGFBI-/- corneas (C, D). All micrographs taken represent the central anterior 
stroma, and the subsequent morphometric analysis relied on five randomly chosen TEM 
micrographs per cornea. Collagen fibril diameter (n = 250) and center-to-center interfibrillar 
spacing (n = 250) were measured and compared between the TGFBI+/+ and TGFBI-/- groups. 
The morphometric analysis showed no change in collagen fibril diameter (mean: 30±3 vs. 
31±3nm), whereas interfibrillar spacing increased slightly in the TGFBI-deficient cornea 
(58±10nm vs. 62±11). Scale bar = 500nm. 
 
 
